Genprex (NASDAQ:GNPX) Releases Quarterly Earnings Results

Genprex (NASDAQ:GNPX) issued its earnings results on Friday. The company reported ($5.00) earnings per share for the quarter, Zacks reports.

Genprex Trading Up 7.0%

NASDAQ:GNPX traded up $0.29 during midday trading on Friday, hitting $4.43. 201,919 shares of the company traded hands, compared to its average volume of 828,077. The firm’s fifty day moving average is $10.32 and its 200-day moving average is $11.86. The firm has a market capitalization of $5.56 million, a P/E ratio of -0.05 and a beta of -0.74. Genprex has a 12-month low of $3.90 and a 12-month high of $84.50.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on GNPX shares. Wall Street Zen raised Genprex to a “sell” rating in a report on Saturday, October 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Genprex in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.